Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Peters

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Clinical and Translational Radiation Oncology|November 2, 2020
Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient's perspectiveMarieke van Son, Evelyn Monninkhof, Max Peters, et al.
Urologic Oncology|December 23, 2022
The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenonArnas Rakauskas, Max Peters, Daniel Ball, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2021
In Reply to Murgic and ChungMarieke Juliet van Son, Max Peters, Marinus A Moerland, et al.
Cancers|December 6, 2018
Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future PerspectivesMarieke van Son, Max Peters, Marinus Moerland, et al.
International Journal of Radiation Oncology, Biology, Physics|July 23, 2019
In Reply to David and KamravaMarieke Juliet van Son, Max Peters, Marinus A Moerland, et al.
European Urology Oncology|June 16, 2026
Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE TrialsAlexander Light, Max Peters, Archana Gopalakrishnan, et al.
Clinical and Translational Radiation Oncology|April 17, 2023
The impact of schizophrenia spectrum disorder, bipolar disorder and borderline personality disorder on radiotherapy treatment and overall survival in cancer patients: A matched pair analysisMax Peters, Hajo W Boersma, Peter S N van Rossum, et al.
International Journal of Radiation Oncology, Biology, Physics|April 15, 2022
In Reply to Chow and SimonePim J J Damen, Tiuri E Kroese, Max Peters, et al.
Clinical and Translational Radiation Oncology|December 28, 2020
Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patientsMarieke van Son, Max Peters, Marinus Moerland, et al.
Plos One|January 18, 2023
Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched studyArnas Rakauskas, Max Peters, Paul Martel, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Clinical and Translational Radiation Oncology|November 2, 2020
Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient's perspectiveMarieke van Son, Evelyn Monninkhof, Max Peters, et al.
Urologic Oncology|December 23, 2022
The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenonArnas Rakauskas, Max Peters, Daniel Ball, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2021
In Reply to Murgic and ChungMarieke Juliet van Son, Max Peters, Marinus A Moerland, et al.
Cancers|December 6, 2018
Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future PerspectivesMarieke van Son, Max Peters, Marinus Moerland, et al.
International Journal of Radiation Oncology, Biology, Physics|July 23, 2019
In Reply to David and KamravaMarieke Juliet van Son, Max Peters, Marinus A Moerland, et al.
European Urology Oncology|June 16, 2026
Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE TrialsAlexander Light, Max Peters, Archana Gopalakrishnan, et al.
Clinical and Translational Radiation Oncology|April 17, 2023
The impact of schizophrenia spectrum disorder, bipolar disorder and borderline personality disorder on radiotherapy treatment and overall survival in cancer patients: A matched pair analysisMax Peters, Hajo W Boersma, Peter S N van Rossum, et al.
International Journal of Radiation Oncology, Biology, Physics|April 15, 2022
In Reply to Chow and SimonePim J J Damen, Tiuri E Kroese, Max Peters, et al.
Clinical and Translational Radiation Oncology|December 28, 2020
Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patientsMarieke van Son, Max Peters, Marinus Moerland, et al.
Plos One|January 18, 2023
Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched studyArnas Rakauskas, Max Peters, Paul Martel, et al.
Pageof 10